Coronavirus. It’s all everyone is talking about. From the media to investors to your uber driver. However, the bombardment of information, particularly from the media, is causing overinflating the coronavirus fear. Many investors saw nothing but red in their portfolios as the fear drove down the ASX by 9.58% last week. If we think logically, […]
Category Archives: Pharmaceutical and Biotechnological Stocks
Here’s why PAR is worth watching now more than ever?
When thinking of a biotech market mover Paradigm Biopharmaceuticals (ASX: PAR) instantly comes to mind. Paradigm, through its repurposed drug Zilosul, aims to alleviate the suffering and cartilage degradation of Osteoarthritis. PAR’s impressive clinical developments in osteoarthritis and 240% surge in 2019 captivated both the scientific and investment world. Paradigm kickstarted 2020 off with a […]
Here’s why CUV is worth holding throughout the Coronavirus panic?
It is rare to discover a sensational biotech from Australia. Why? Because when we search for quality Biotechs our eyes look to Europe. Especially, as the European countries like England, Germany, Belgium and Switzerland pride themselves on their extensive research. Just think of the most reputable biotechs in Europe such as Cambridge Antibody Technology, Micromet […]
Will PAR’s H1 2020 financials trigger a surge this week?
In my opinion, biotechnology is the most entertaining industry in the stock market. Why? Three reasons. 1) Biotech tends to be up even when the market is down. Because our ageing population continues to demand the best medicine to sustain a higher life expectancy. 2) Second, there is a range of top-quality biotechs under […]
Does CUV’s 45% plummet provide a golden opportunity for investors?
Have you heard of Clinuvel Ltd (ASX: CUV)? The skin disorder company is famous in Germany and Australia. Clinuvel captivated investors in 2019 with an impressive 150% surge, leading to their high of $45 in October. However, CUV decreased 43% since its $45 high. Today we will discuss why Clinuvel’s plummet is an opportunity, what […]
CSL up 928% in 10 years, will the exponential growth continue in 2020?
Commonwealth Serum Laboratories ASX: CSL, is one of the world’s most talked-about biotech companies. Therefore, it is no surprise that when CSL reached $321 (5/02/2020) the media attention surrounding the company exploded. Today we are discussing CSL’s financials, 2020 outlook and whether they are worth the investment in 2020. Financials Positives Investor excitement around CSL […]
Will IMU’s cancer trials cause a surge in stock price?
Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. Imugene Ltd (ASX:IMU) has one of the most exciting stock stories in the biotech industry. Why? Because IMU strives to cure cancer, through a range of new Immuno oncology therapies. […]
Why this ASX cannabis stock is the only one worth watching in 2020?
Every cannabis stock has its story. Ecofibre (ASX: EOF) experienced an 88% YTD increase since listing at $1.70 back in March 2019. Unlike, your traditional cannabis company EOF operates under a unique business model. EOF’s cannabis footprint covers medicinal cannabis, plant-based protein and HEMP. EOF strives to use cannabis to change people’s lives. First, by […]
Has the coronavirus created a possible entry for PAR ?
Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. If you have not heard of Paradigm BioPharmaceuticals (ASX: PAR) then today is your lucky day. PAR is an Australian BioPharmaceutical company that aims to alleviate the cartilage degradation of […]
ASX cannabis stock plunges 90%, could this opportunity allow investors to enter the cannabis market for 2020?
ASX cannabis stocks are speculative. Australia has no clear cannabis leader. Because of the bearish storm that brought most of the industry down in 2019. Today we analyse whether Creso Pharma’s decrease provides market entry for investors? Creso Pharma (CPH) is an Australian cannabis company with operations in Israel, Australia, Colombia, Canada, and Switzerland. CPH […]
Update: Will Paradigm’s stock price surge continue into 2020?
Why all the excitement in 2019? Paradigm Biopharmaceuticals captivated investors with an impressive 300% rise over 2019. Paradigm aims to alleviate the suffering and cartilage degradation of Osteoarthritis through their repurposed drug Zilosul. PAR’s rapid stock rise was due to the company’s outstanding collection of clinical data on Zilosul. For any Biotech to achieve success, […]
Does IMU’s 2020 cancer ‘cure’ clinical trials hold exponential stock growth?
Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. Is there a cure for cancer? A question that instantly makes the scientific world wonder. However, creating a viable solution to cancer is difficult to prove. Because biotechnological and medical […]
Cann Group losing value as bearish market trend sets in – How much more will investors take?
Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. Introduction Cann Group (CAN) Cann Group (CAN) is an Australian medicinal cannabis company. Cann aims to research, cultivate, and manufacture a range for medicinal cannabis products for patients in Australia […]
AusCann holds major potential in Australian medicinal market?
Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. Short Intro on medicinal cannabis Medicinal cannabis, unlike HEMP and recreational, already has the legislative framework for pharmaceutical companies to prescribe to patients. Medicinal cannabis (CBD) is from both the […]
Paradigm Bio-Pharmaceutical (ASX) with major stock movement- how long will it hold ?
Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. Since launching , YIG has published articles relating to commodities (Cobalt) and Tech companies. Now, YIG has a new and exciting list of companies that will be assessed, to give […]